問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Koo Foundation Sun Yat-Sen Cancer Center (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

黃敬元
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃敬元

List

9Cases

2021-04-01 - 2027-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Not yet recruiting17Sites

2022-12-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-08-01 - 2027-04-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting2Sites

Recruiting3Sites

2020-01-01 - 2029-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting6Sites

2024-09-01 - 2038-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2022-04-01 - 2027-03-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2022-04-01 - 2027-03-26

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2019-04-01 - 2022-03-03

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2020-08-14 - 2027-07-24

Phase III

A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

  • Condition/Disease

    Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    DEBIO 1143

Participate Sites
10Sites

Recruiting8Sites

Terminated2Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB